User: Guest  Login
Less Searchfields
Simple search
Title:

Efficacy and Safety of Trastuzumab Emtansine Plus Capecitabine vs Trastuzumab Emtansine Alone in Patients With Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Phase 1 and Randomized Phase 2 Trial.

Document type:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
Author(s):
Cortés, Javier; Diéras, Véronique; Lorenzen, Sylvie; Montemurro, Filippo; Riera-Knorrenschild, Jorge; Thuss-Patience, Peter; Allegrini, Giacomo; De Laurentiis, Michelino; Lohrisch, Caroline; Oravcová, Eva; Perez-Garcia, Jose M; Ricci, Francesco; Sakaeva, Dina; Serpanchy, Rosanne; Šufliarský, Jozef; Vidal, Maria; Irahara, Natsumi; Wohlfarth, Christine; Aout, Mounir; Gelmon, Karen
Abstract:
Importance: ERBB2 (HER2)-targeted therapy provides benefits in metastatic breast cancer (mBC) and gastric cancer, but additional treatments are needed to maximize efficacy and quality of life. Objective: To determine maximum tolerated doses (MTDs) of trastuzumab emtansine (T-DM1) plus capecitabine in patients with previously treated ERBB2-positive mBC and locally advanced/metastatic gastric cancer (LA/mGC) (phase 1) and the efficacy and safety of this combination vs T-DM1 alone in patients with...     »
Journal title abbreviation:
JAMA Oncol
Year:
2020
Journal volume:
6
Journal issue:
8
Pages contribution:
1203-1209
Fulltext / DOI:
doi:10.1001/jamaoncol.2020.1796
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/32584367
Print-ISSN:
2374-2437
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)
 BibTeX